Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.68 extracted from

  • Marder, V.J.
    Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator (2008), Thromb. Res., 122 Suppl 3, S9-S15.
    View publication on PubMedView publication on EuropePMC

Application

Application Comment Organism
medicine in comparison with t-PA, plasmin shows a distinct benefit-to-risk advantage. Plasmin is equally effective as t-PA in thrombolysis and may be superior for treating thrombi in totally-occluded vessels. Whereas t-PA causes bleeding from vascular trauma sites in animals when infused at dosages used for thrombolysis (0.5-1 mg/kg), plasmin exhibits safety at therapeutic dosages. Plasmin can be used at several fold higher concentrations than is needed for thrombolysis, thereby providing a significant safety margin that is not attainable for t-PA Oryctolagus cuniculus
medicine plasmin is a suitable alternative to t-PA as it causes less bleeding but has equivalent or greater thrombolytic efficacy Homo sapiens

Cloned(Commentary)

Cloned (Comment) Organism
-
Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-
Oryctolagus cuniculus
-
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
plasminogen + H2O
-
Oryctolagus cuniculus plasmin + ?
-
?
plasminogen + H2O patients suffering intracranial hemorrhage or cerebral infarction after receiving 100 mg t-PA for acute myocardial infarction Homo sapiens plasmin + ?
-
?

Synonyms

Synonyms Comment Organism
t-PA
-
Homo sapiens
t-PA
-
Oryctolagus cuniculus
Tissue plasminogen activator
-
Homo sapiens
Tissue plasminogen activator
-
Oryctolagus cuniculus